Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States

Takeda launches sleep disorder pill in the U.S after DEA clearance removes final hurdle

Takeda 4502.T said on Thursday its narcolepsy pill, the first treatment to target the underlying cause of the rare sleep disorder, is now available in the U.S. after a Drug Enforcement Administration decision removed the final regulatory hurdle for its rollout.

Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle - Regional Media News

By Siddhi Mahatole and Sriparna Roy Nov 12 (Reuters) - Takeda said on Thursday its narcolepsy pill, the first treatment to target the underlying cause of the rare sleep disorder, is now available in the US after a Drug Enforcement Administration decision removed the final [...]

Takeda launches new narcolepsy pill as DEA completes scheduling

Takeda (TAK) launches Orzeyful in the U.S. for adults with narcolepsy type 1 after the DEA assigns the orexin agonist Schedule IV status. Read more here.

Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle

By Siddhi Mahatole and Sriparna Roy Nov 12 (Reuters) - Takeda said on Thursday its narcolepsy pill, the first treatment to target the underlying cause of the rare sleep ​disorder, is now available in the US after a ‌Drug Enforcement Administration deci...

Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 12, 2026-

First Orexin Agonist for Narcolepsy Type 1 Now Available in US

The DEA has placed the newly launched oral orexin receptor 2 agonist in schedule IV of the Controlled Substances Act, clearing the way for its use in adults with narcolepsy type 1.